AstraZeneca’s COVID-19 vaccine data fails to impress Wall Street analysts with its effectiveness in clinical trials
November 23, 2020 at 13:38 PM EST
AstraZeneca’s experimental COVID-19 vaccine is the third vaccine to demonstrate it can prevent coronavirus infections in a late-stage clinical trial, though the viral vector-based vaccine is much less efficacious than the other leading vaccine candidates.
